VCEL — Vericel Corporation

Summary of Vericel Corporation (VCEL) Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $92.9 million, a 23% increase year-over-year, exceeding guidance.
• MACI Revenue: $84.1 million in Q4, also up 23% year-over-year and 51% sequentially from Q3.
• Full Year Revenue: $276.3 million, surpassing the high end of guidance.
• Gross Margin: Nearly 80% in Q4; 74% for the full year, an increase of nearly 200 basis points year-over-year.
• Adjusted EBITDA Margin: 40% in Q4; 26% for the full year, up over 300 basis points year-over-year.
• Net Income: Grew nearly 60% to $16.5 million for the full year.
• Cash Position: Approximately $200 million in cash and investments, with no debt.

2. Strategic Updates and Business Highlights

• MACI Sales Force Expansion: Successfully completed, enhancing market reach and driving deeper penetration among existing surgeons.
• MACI Ankle Clinical Study: Initiated the Phase III MACI Ankle MASCOT study, targeting a potential $1 billion market.
• International Expansion Plans: On track to submit a marketing authorization application in the U.K. in mid-2026, with a potential launch in 2027.
• Surgeon Training: Approximately 1,000 surgeons trained in the MACI Arthro technique, leading to increased biopsy and implant growth.
• NexoBrid Adoption: Continued progress in reactivating dormant Epicel accounts and expanding NexoBrid usage.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected total revenue of $316 million to $326 million, with MACI revenue projected at $280 million to $286 million.
• Q1 2026 Guidance: Anticipating MACI revenue of $54 million to $55 million and Burn Care revenue of $9 million to $10 million.
• Margin Expectations: Gross margin projected at approximately 75% and adjusted EBITDA margin at around 27% for the full year.
• Operating Expenses: Estimated at $220 million for 2026, reflecting sales force expansion and increased R&D expenses.

4. Bad News, Challenges, or Points of Concern

• Pricing vs. Volume Growth: Concerns raised regarding the balance between price increases and volume growth, with some analysts questioning if price was a significant driver of recent revenue increases.
• Guidance Caution: 2026 MACI revenue guidance implies growth slightly below previous expectations (18% vs. 20%).
• Regulatory Delays: Potential delays in BARDA funding and regulatory approvals could impact future revenue from NexoBrid and MACI.

5. Notable Q&A Insights

• Surgeon Growth Dynamics: Approximately two-thirds of new MACI Arthro surgeons are existing users, indicating a mix of new and repeat surgeon growth.
• Sales Force Productivity: Management expects productivity to return to 2025 levels quickly, but no specific enhancements from the new sales force were baked into guidance.
• NexoBrid and BARDA Funding: While optimistic about BARDA funding, specifics on revenue contributions remain uncertain pending negotiations.
• MACI Arthro Performance: Surgeons trained in MACI Arthro show higher conversion rates and growth metrics, indicating a positive trend for future revenue.

Overall, Vericel demonstrated strong financial performance in Q4 2025, with strategic initiatives in place for sustained growth. However, the company faces challenges related to pricing dynamics, regulatory uncertainties, and cautious guidance for 2026.